FDA approves Mounjaro heart-risk indication and tirzepatide label updates from SURPASS-CVOT
Both tirzepatide brands now carry heart-trial information in their labels, and Mounjaro has a new cardiovascular indication, which can shape how doctors and insurers treat the drug.
The FDA has approved labeling supplements for Eli Lilly's two tirzepatide products, adding results from a cardiovascular outcomes trial to the prescribing information for both and a new heart-risk indication for Mounjaro, according to approval letters posted by the agency [1][2].
The Mounjaro action covers two prior approval supplements. One adds an indication for reducing the risk of major adverse cardiovascular (CV) events — CV death, non-fatal myocardial infarction or non-fatal stroke — in adults with type 2 diabetes who are at high risk for those events [2]. The other updates the Mounjaro prescribing information to state that the 2.5 mg dose of tirzepatide can be used for ongoing glycemic control in patients with type 2 diabetes [2]. The supplements were received October 27 and November 5, 2025, and the approval letters were signed August 27, 2026 [2].
The Zepbound supplement updates the prescribing information with information from the same trial, including changes to the Warnings and Precautions section on diabetic retinopathy complications in patients with a history of diabetic retinopathy, plus revisions to Patient Counseling Information to align with the Dosage and Administration section [1]. That application was dated October 24, 2025, received October 27, 2025, and approved effective August 26, 2026 [1]. The Zepbound letter does not list a new cardiovascular risk-reduction indication, the way the Mounjaro letter does [1][2].
The trial behind both labels is I8F-MC-GPGN, titled The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT). It was conducted in adults with type 2 diabetes and established cardiovascular disease and compared tirzepatide with dulaglutide [1][2]. The letters describe which label sections changed but do not include the trial's numerical results — patient numbers, event rates or hazard ratios. Those figures have not been disclosed in these documents.
The FDA also issued a corrected Zepbound approval letter dated September 2, 2026. It says the previously approved versions of the Medication Guide, the Instructions for Use for the single-dose vial and the Instructions for Use for the single-dose pen attached to the August 26 letter were not the most recent versions. The effective action date remains August 26, 2026 [3].
On pediatric requirements, the FDA waived studies for the Mounjaro glycemic-control supplement because the condition rarely or never occurs in pediatric populations, and said the other two supplements were exempt [1][2].
Why it matters for patients
The indication section of a drug label describes what the product is FDA-approved to treat, and it often influences insurance coverage, formulary placement and clinical guidelines. For adults with type 2 diabetes and established cardiovascular disease, the Mounjaro label now states a heart-risk reduction use [2]. Zepbound, which contains the same active ingredient, tirzepatide, received trial information and retinopathy-related warning changes but no cardiovascular indication in its approval letter [1].
Both letters say the Warnings and Precautions language about diabetic retinopathy complications in patients with a history of diabetic retinopathy was changed based on SURPASS-CVOT [1][2]. Neither letter states the new wording or whether the warning was strengthened or narrowed, so those details are not yet public. The Mounjaro 2.5 mg change addresses whether that dose counts for ongoing blood sugar control, not just as a starting dose [2]. Nothing in the letters addresses pricing, copays or supply.
What happens next
Several deadlines now apply to Lilly. Within 14 days of each approval letter, the company must submit the label content in structured product labeling format using the FDA's automated drug registration and listing system [1][2]. Within 7 days it must submit a statement of intent to comply with rules on promotional materials [1][2]. Within 30 days it must file certain patent information for Orange Book listing [1][2].
The FDA says the structured product labeling will be accessible from publicly available labeling repositories, but the letters give no date for when patients or clinicians will see the revised labels in full [1][2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.